High-flow nasal cannula is an expensive and clunky placebo: myth or maxim?
File(s)
Author(s)
Jones, Gareth AL
Ramnarayan, Padmanabhan
Type
Journal Article
Abstract
High-flow nasal cannula (HFNC) is now a commonly used noninvasive method of providing respiratory support to children and young people. Its rapid spread into varied clinical applications has often left assessment of the evidence of its mechanism of action and clinical benefit lagging behind its uptake. This review will discuss the proposed mechanisms of action of HFNC, review the evidence base for its use, cover its applications in paediatrics and outline its limitations.
Date Issued
2024-10-01
Date Acceptance
2024-08-08
Citation
Breathe, 2024, 20 (3)
ISSN
1810-6838
Publisher
European Respiratory Society
Journal / Book Title
Breathe
Volume
20
Issue
3
Copyright Statement
Copyright ©ERS 2024 Breathe articles are open access and distributed under the terms of the Creative Commons Attribution Non-Commercial Licence 4.0. For commercial reproduction rights and permissions contact permissions@ersnet.org
License URL
Identifier
https://www.ncbi.nlm.nih.gov/pubmed/39660088
PII: EDU-0185-2023
Subjects
ASTHMA
BRONCHIOLITIS
CHILDREN
HFNC
INFANTS
Life Sciences & Biomedicine
OXYGEN-THERAPY
POSITIVE AIRWAY PRESSURE
Respiratory System
Science & Technology
TRIAL
Publication Status
Published
Coverage Spatial
England
Article Number
230185
Date Publish Online
2024-12-10